BOBULSKY SUSAN sold $102K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 5,000 shares of Adaptive Biotechnologies Corp (ADPT) at $20.50 ($0.10M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Jun 29, 2026, 11:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 11:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

This is a pre-arranged 10b5-1 open-market sale by a senior officer; it is typically not a strong standalone catalyst for price action.

02

Market read

Confirms a scheduled insider sale (5,000 shares at $20.50) with limited incremental information for trading decisions.

03

What to watch

The article provides no context on total insider holdings beyond the post-transaction figure, and does not indicate any change in company fundamentals—so the signal-to-noise is low.

Relevance 3/10Novelty 5/10Timing: filed 2026-06-29 after-hours; transaction dated 2026-06-25

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Adaptive Biotechnologies insider (Chief Commercial Officer) sold 5,000 shares at $20.50 on 2026-06-25 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No direct sector read-through; this is company-specific insider liquidity rather than a biotech/clinical catalyst.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can still coincide with internal confidence if the plan is simply executed on schedule; traders may overreact to the headline framing of “selling.”

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction disclosure.

  • BOBULSKY SUSAN

    Chief Commercial Officer (MRD) who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.